2 Killer Growth Stocks to Buy Right Now and Hold for the Long Term

Canadian investors should look to snatch up killer growth stocks like Nuvei (TSX:NVEI) on the dip.

| More on:

The S&P/TSX Composite Index was up 152 points in late-morning trading on November 1. Some of the top-performing sectors included base metals, energy, and information technology. Today, I want to zero in on two killer growth stocks that are worth snatching up, as we enter the final two months of a hectic 2022. Let’s dive in.

This growth stock offers exposure to the payment technology market space

Nuvei (TSX:NVEI) is a Montreal-based company that provides payment technology solutions to merchants and partners in North America and around the world. Shares of this top growth stock have plunged 50% in 2022 as of early afternoon trading on November 1. The growth stock is down 73% year over year.

Precedence Research recently estimated that the global digital payment market was worth US$89.5 billion in 2021. The payment processing segment held a quarter of the market share in 2021 according to this report. This researcher projects that this market will rise to a valuation of US$374 billion by 2030. That would represent a strong compound annual growth rate (CAGR) of 17% from 2022 through to the end of the forecast period.

This company released its second-quarter fiscal 2022 results on August 9. It delivered total volume growth of 38% to $30.1 billion, while revenue increased 19% to $211 million. Meanwhile, Nuvei reported adjusted net income of $74.7 million, or $0.51 per diluted share — up from $64.5 million, or $0.44 per diluted share, in the second quarter of fiscal 2021. Free cash flow jumped 11% to $80.8 million.

Investors who snatch up this exciting growth stock get access to a burgeoning payment technology sector.

Don’t sleep on this telehealth-focused Canadian growth stock in 2022

WELL Health Technologies (TSX:WELL) is the second top growth stock I’d look to snatch up to kick off the month of November. This Vancouver-based company operates as a practitioner-focused digital health company across North America and around the world. Shares of this growth stock have declined 41% in the year-to-date period at the time of this writing.

Nova One Advisor, a worldwide market researcher, recently estimated that the United States Telehealth market was valued at US$23.8 billion in 2021. That is expected to grow to US$309 billion in 2030. This would represent a CAGR of 45% from 2022 through to the end of the forecast period. Meanwhile, Fortune Business Insights also projected that the global telehealth market would achieve a CAGR of 32% from 2021 through to the end of 2028, hitting a valuation of US$636 billion.

The company unveiled its second-quarter fiscal 2022 earnings on August 11. WELL Health delivered quarterly revenue growth of 127% to $140 million. Meanwhile, it posted adjusted net income of $17.2 million compared to an adjusted net loss of $1.2 million in the second quarter of fiscal 2021. This spurred WELL Health to bolster its guidance for annual revenue in 2022 to rise above $550 million.

This growth stock is trading in favourable value territory compared to its industry peers at the start of November. Moreover, it is set to deliver strong revenue growth going forward.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has positions in Nuvei Corporation. The Motley Fool has positions in and recommends Nuvei Corporation. The Motley Fool has a disclosure policy.

More on Investing

Middle aged man drinks coffee
Dividend Stocks

Is Brookfield Stock a Buy, Sell, or Hold for 2025?

BAM stock recently jumped after beating earnings. But is it still a buy, or is it better to wait?

Read more »

Make a choice, path to success, sign
Dividend Stocks

Is Fortis Stock a Buy for its Dividend Yield?

Fortis has increased the dividend for 51 consecutive years.

Read more »

oil and gas pipeline
Energy Stocks

Is TC Energy Stock a Good Buy?

TC Energy stock has a lot going for it, but there are also a few red flags to consider before…

Read more »

Electricity transmission towers with orange glowing wires against night sky
Dividend Stocks

3 Top Canadian Utility Stocks to Buy in November

Are you looking for some top Canadian utility stocks to own? Here's a look at three must-have options for any…

Read more »

View of high rise corporate buildings in the financial district of Toronto, Canada
Dividend Stocks

Is First Capital REIT a Buy for its 4.8% Yield?

First Capital is a REIT that offers you a tasty dividend yield of 4.8%. Is this TSX dividend stock a…

Read more »

TFSA (Tax free savings account) acronym on wooden cubes on the background of stacks of coins
Dividend Stocks

TFSA Passive Income: 3 Stocks to Buy and Never Sell

Stocks like Fortis Inc (TSX:FTS) are worth holding long term.

Read more »

Electricity transmission towers with orange glowing wires against night sky
Dividend Stocks

Canadian Utility Stocks to Buy Now for Stable Returns

Given their regulated business, falling interest rates, and healthy growth prospects, these three Canadian utility stocks are ideal for earning…

Read more »

Investor reading the newspaper
Investing

Is Couche-Tard Stock a Buy, Sell, or Hold for 2025?

Let's dive into whether Alimentation Couche-Tard (TSX:ATD) is a top stock to buy, sell, or hold in the coming year.

Read more »